YAP1 and cancer: Aberrant activation of YAP1 has been implicated in the initiation and progression of various cancers, including lung, mesothelioma, gastric, and colorectal cancers, where it is associated with poor prognosis and resistance to targeted therapies [9,10,11,12,13].